Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study (Q34332159)

1 August 2017

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study (English)

1 reference

1 August 2017

0 references

Samantha Burnham

2

0 references

Pierrick Bourgeat

Pierrick Bourgeat

3

0 references

Cassandra Szoeke

Cassandra Szoeke

7

0 references

Olivier Salvado

Olivier Salvado

6

0 references

Paul Maruff

Paul Maruff

10

0 references

Kathryn A Ellis

Kathryn A Ellis

5

0 references

Ralph Martins

Ralph Martins

9

0 references

Colin L. Masters

13

Colin L Masters

1 reference

1 August 2017

Victor L Villemagne

1

1 reference

1 August 2017

Belinda Brown

4

1 reference

1 August 2017

S Lance Macaulay

8

1 reference

1 August 2017

David Ames

11

1 reference

1 August 2017

Christopher C Rowe

12

1 reference

1 August 2017

Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group

14

1 reference

1 August 2017

8 March 2013

1 reference

1 August 2017

1 reference

1 August 2017

12

1 reference

1 August 2017

357-367

1 reference

1 August 2017

4

1 reference

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Testing the right target and right drug at the right stage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Frequent amyloid deposition without significant cognitive impairment among the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Revising the definition of Alzheimer's disease: a new lexicon.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

Intra-individual variability in Alzheimer's disease and cognitive aging: definitions, context, and effect sizes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

The Alzheimer's disease neuroimaging initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970044-9

7 January 2021

10.1016/S1474-4422(13)70044-9

Identifiers

DOI

1 reference

1 August 2017

1 reference